Mycetoma Clinical Trial
Official title:
A Randomized, Double Blind Phase II Proof-of-Concept Superiority Trial of Fosravuconazole 200 mg or 300 mg Weekly Dose Versus Itraconazole 400 mg Daily, All Three Arms in Combination With Surgery, in Patients With Eumycetoma in Sudan
This study is a single-center, comparative, randomized, double-blind, parallel-group,
active-controlled, clinical superiority trial of Fosravuconazole versus Itraconazole
combined with surgery in subjects with eumycetoma in Sudan.
There will be three arms in this study: The first arm will be Fosravuconazole 300 mg weekly,
the second arm will have Fosravuconazole 200 mg weekly and the control arm is the standard
treatment using itraconazole 400mg daily.
At 3 months time-point, interim analysis will be done and one of the study arms will be
dropped according to the drop-the-loser design, based on efficacy or toxicity.
Eumycetoma is a fungal disease caused by Madurella mycetomatis. The disease is chronic,
granulomatous and inflammatory. It usually involves subcutaneous tissues and leads to masses
and sinuses from which fungal grains are discharged. It is most probably introduced post
trauma e.g. thorn prick. It is associated with major morbidity and can be disabling,
disfiguring and highly stigmatizing. In advanced cases it may be fatal. Eumycetoma is most
prevalent in what is known as mycetoma belt.
Current treatment modalities for eumycetoma are disappointing. The response is characterized
by low cure rates, high amputation rates, high up drop out from follow up and high
recurrence rates. The available drugs for the treatment of eumycetoma are expensive,
potentially toxic and require a long treatment period up to 12 months. By that time the mass
is well encapsulated and is removed surgically. Despite prolonged medical treatment, the
causative organisms are commonly found to still be viable and can be cultured from the
surgical specimen.
The objectives of this study are to determine the comparative efficacy, safety, and
tolerability of Fosravuconazole versus itraconazole as first-line treatment for subjects
with eumycetoma caused by Madurella mycetomatis. The primary end-point will be complete cure
after 12 months treatment as evidenced by clinical assessment showing absence of mycetoma
mass with closure of sinuses and absent discharge, normal ultrasonic examination of the
lesion, or the presence of fibrosis only associated with a negative fungal culture from a
surgical biopsy from the former mycetoma site. The secondary endpoints are the outcome at
3-month's time point based on the same criteria as 12 month and/or treatment-related adverse
events at the 3- and 12-month visits. The study will also monitor plasma drug levels of
ravuconazole and itraconazole that will be included in a logistic model with other clinical
and laboratory parameters to predict outcome. In addition, immunological studies will be
done to describe the developing or changing immune responses during treatment. Lastly, all
strains collected will be cultured and typed and with assessment of antifungal resistance.
This study is a single-center, comparative, randomized, double-blind, parallel-group,
active-controlled, clinical superiority trial in subjects with eumycetoma requiring surgery.
There will be three arms this study: The first arm will have Fosravuconazole 300 mg weekly
and the second arm will have Fosravuconazole 200 mg weekly. Both arms will be evaluated at 3
months. At this time-point, one of the study arms will be dropped according to the
drop-the-loser design, based on efficacy or toxicity. The control arm is the standard
treatment using itraconazole 400mg daily. Patients will receive treatment for one year. An
interim analysis is planned after data has been accumulated for sample size of 28 for 3
months end point.
This study will be done at the Mycetoma Research Centre, Sudan when ethics and regulatory
approvals are received. The study plans to recruit 138 subjects by the end of the trial. The
main inclusion criteria are subjects who provide consent, aged 18 years or more with primary
moderate eumycetoma (size 2-10 cm) caused by Polymerase Chain Reaction (PCR) confirmed
Madurella mycetomatis. Females in the child bearing age will require stringent
contraception. The main exclusion criteria are eumycetoma > 10 cm, previous treatment,
significant concomitant illness that preclude evaluation and treatments or conditions
treated with drugs that are known to interact with the azoles.
The study is expected to new safer and more efficacious eumycetoma treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04401969 -
Tissue Microenvironment Signatures of the Mycetoma Granuloma
|